Sunday, 1 June 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 01 June 2025
News

US invests in Aussie candidate

Posted 14 May 2025 PM

US-based non-profit, Critical Path Institute, has invested $1.25 million in a new treatment for advanced and therapy-resistant prostate cancer, at the University of Queensland.

The grant falls under Critical Path Institute’s Translation Therapeutics Accelerator program (TRxA), which seeks to advance cutting-edge therapeutics from the lab to patients. The funding injection will cover critical preclinical studies, process optimisation, drug substance manufacturing and safety studies, paving the way for the drug dubbed QED-203 to potentially advance to human clinical trials.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (21)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.